Chronic spontaneous urticaria — hives lasting longer than six weeks without an identifiable trigger — is one of the more frustrating presentations in community pharmacy. The standard advice is a non-sedating antihistamine at the licensed dose, and for many patients that works. For the minority whose wheals persist despite daily loratadine or cetirizine, the next step often surprises patients: UK and European guidelines support up-dosing the same antihistamine, off-label, to up to four times the licensed dose before moving to specialist treatment.

This article summarises the relevant UK guidance, what the evidence supports, and where the specialist referral threshold sits.

What chronic urticaria is

NICE CKS defines chronic urticaria as episodes of urticaria lasting more than six weeks, occurring daily or near-daily. Most cases are spontaneous — no identifiable external trigger — and the underlying mechanism is autoimmune or idiopathic mast-cell activation rather than an external allergen. Patch testing, food elimination and blood work rarely reveal a specific cause.

Symptoms include wheals (raised, itchy, transient skin swelling that resolves within 24 hours), angioedema in some patients, and considerable impact on sleep and quality of life. The condition is distinct from acute urticaria (under six weeks, often post-viral or drug-induced) and from chronic inducible urticaria (triggered by specific physical stimuli such as cold or pressure).

First-line: standard-dose non-sedating antihistamine

NICE, BSACI and the joint EAACI/GA²LEN/EDF/WAO international guideline all recommend a non-sedating oral H1-antihistamine at the licensed dose as first-line. Options available in the UK include:

If symptoms are controlled on the licensed dose, treatment typically continues for the duration of the episode, with periodic trials off treatment to see whether the condition has resolved.

Up-dosing: the second-line that surprises patients

Where licensed-dose antihistamines don't control symptoms after two to four weeks, the EAACI/GA²LEN/EDF/WAO guideline — endorsed by BSACI and referenced by NICE CKS — recommends increasing the same non-sedating antihistamine to up to four times the licensed daily dose before adding further treatment.

In practice, that means a loratadine user who has not responded to 10 mg daily may be advised by their clinician to move to 20 mg, then 30 mg, then 40 mg daily, in stepwise increments. The evidence base is a series of randomised controlled trials showing improved symptom control at up-dosed regimens without proportional increases in sedation or anticholinergic side effects for the non-sedating agents.

Three important points for the pharmacy consultation:

1. Up-dosing is off-label. The marketing authorisations for loratadine, cetirizine and peers do not cover doses above the standard 10 mg (or equivalent). Up-dosing is a guideline-supported clinical decision, not a licensed indication.
2. It applies to non-sedating antihistamines only. Older sedating antihistamines (chlorphenamine, promethazine) are not suitable for up-dosing; they are no longer first-line for chronic urticaria.
3. Patients should be on up-dosed treatment under clinical supervision. A pharmacist can reassure a patient that the regimen is guideline-backed, but decisions to move beyond the licensed dose should involve the GP or specialist, and the regimen should be documented.

Third-line: specialist referral

Where up-dosed non-sedating antihistamines do not control symptoms, the guideline recommends specialist referral for consideration of:

• Omalizumab — an anti-IgE monoclonal antibody licensed in the UK for chronic spontaneous urticaria refractory to H1-antihistamines. NICE TA339 recommends omalizumab as an option for patients meeting specific criteria.
• Ciclosporin — a calcineurin inhibitor with trial evidence in severe refractory urticaria, used under specialist supervision.
• Montelukast — a leukotriene receptor antagonist, with limited evidence but sometimes used as an adjunct.

The referral threshold, per NICE CKS, is typically chronic urticaria that has not responded to six weeks of up-dosed antihistamine treatment, or where symptoms cause significant quality-of-life impact despite treatment.

What community pharmacy can and can't do

Pharmacy First in England does not cover chronic urticaria — there is no PGD for antihistamine supply in this condition, and the service is designed for acute, self-limiting presentations. The pharmacy role is therefore:

• Recognising chronic urticaria (persistent or recurrent wheals beyond six weeks).
• Supporting licensed-dose OTC antihistamine use as first-line.
• Explaining that up-dosing is guideline-supported but should be discussed with a GP or specialist, not self-initiated.
• Recognising angioedema (especially of the lips, tongue or airway) as a red flag and referring urgently.
• Supporting medication adherence in patients already on an established regimen.

A patient who arrives at the pharmacy self-medicating with two or three daily loratadine tablets because "one isn't enough" is a conversation opportunity rather than a refusal — the regimen they are describing may well be clinically sensible, but it should be formally reviewed and documented by a prescriber.

Caveats

This article summarises NICE CKS, BSACI guidance and the international joint guideline current to April 2026. Individual patient care should follow the treating clinician's judgement. Doses above the licensed maximum are unlicensed and should be initiated and reviewed by a prescriber.

Sources

• NICE Clinical Knowledge Summaries — Urticaria
• BSACI — Guideline for the management of chronic urticaria
• EAACI/GA²LEN/EDF/WAO — International guideline for the definition, classification, diagnosis and management of urticaria
• NICE Technology Appraisal 339 — Omalizumab for chronic spontaneous urticaria
• British National Formulary — loratadine, cetirizine, fexofenadine

Looking for pharmacy support or a Pharmacy First consultation? Find an NHS community pharmacy via PharmSee's pharmacy finder.